From a mechanistic point of view, mAbs that target CD38 have been described to efficiently erase not only CD38+ tumor cells, but also different populations of CD38+ regulatory cells, which are endowed with the highest immune-modulatory properties and with protective role to such invasive malignant cells against immune system recognition. The gene discussed is CD38; the disease is neoplasm.